• AG真人国际(中国)官方官网

    |
    |
    EN
    • 业务咨询

      中国:

      Email: marketing@videisimo.net

      业务咨询专线:400-780-8018

      (仅限服务咨询,其他事宜请拨打川沙总部电话)

      川沙总部电话: +86 (21) 5859-1500

      海外:

      +1(626)986-9880(U.S. - West Coast)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com

    在线留言×
    点击切换
    News information
    新闻资讯

    A.C.E. Seminar 2: Patent enforcement and clearance for freedom-to-operate in the U.S.

    2023-02-27
    |
    访问量:

    ACE.jpg

    Seminar 2: Patent enforcement and clearance
    for freedom-to-operate in the U.S.

    March 4, 2023 09:00-10:00(ET) March 4, 2023 22:00-23:00 (Beijing)

    Starting from 2023, Medicilon will host a series of webinars with a wide range of critical topics in biotech industry, including IP strategies, licensing, M&A,investment,due diligence, finance, company management, the business environment between United States and China, as well as how Medicilon cansupport with its 20 years of establishment and new research and technology platforms.

    During the webinars, Medicilon will invite a group of senior industrial experts and executives in related fields to systematically introduce the ideas and key elements, share their experience, and conduct the in-depth discussions.We sincerely invite you to join us!

    Welcome Speech Speaker

    xingquan-Ma.png

    Xingquan Ma, Ph.D.

    Senior Vice President, Chemistry Department

    Xingquan Ma, used to be an associate researcher of the Scripps Institute (TSRI) and a visiting scholar of the National lnstitutes of Health (NIH). He received doctor's degree from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. In 2018, he joined Medicilon as Vice President of the Chemical Department.

    Dr. Xingquan Ma has studied and worked at the top academic institutions in China and the US. He has in-depth research in the field of glycan chemistry and biology. He has extensive knowledge and experience in the isolation, extraction and chemical synthesis of saponins, the active ingredients of Chinese herbal medicine. He has more research on the synthesis and biological activity of polysaccharide macromolecular adducts in the frontier field. He is interested in the crystaline structure of cellular membrane proteins,especially in the crystallization of glycolipids on penetrating membrane proteins and the high-resolution analysis of their structures. He has also worked on the synthesis and bioactivity of polyphenols, including teicoplanin, and more complex oligomers.Xingquan Ma, has 12 years of experience in corporate drug discovery and development,and has collaborated with several European and American companies in novel drug research. He has published more than 20 academic papers in domestic and international core journals, including JACS, ANGEW, LANGMUIR,OBC,JMCL. etc.

    Invited Speaker

    Yieyie-Yang.png

    Yieyie Yang, Ph.D., J.D.

    Of Counsel, Finnegan, Henderson, Farabow, Garrett &Dunner, LLP

    Yieyie Yang, Ph.D in Molecular Biology, J.D., is Of Counsel at Finnegan, Henderson,Farabow, Garrett & Dunner, LLP, a top tier global law firm specialized in Intellectua Property legal matters. Dr. Yang has extensive experience representing pharmaceutical and biotech companies in a wide variety of IP matters, including patent prosecution,client counseling, due diligence, licensing, patent post-grant proceedings, patent litigation,and appeal. Dr. Yang has assisted large international pharmaceutical companies such as Eli Lilly, AstraZeneca, AbbVie, GSK, Merck, Novartis, and rising startup biotech companies during fund-raising and early to late R&D stages on IP matters. Specifically,Dr. Yang represented patent owners or petitioners in over 35 IPRS/PGRs involving biotech patents. Dr. Yang was awarded among "Ones to Watch" in 2023 by Best Lawyers for her outstanding professional excellence in private practice in patent law in theUnited States.

    mark.png

    Mark Feldstein, Ph.D., J.D.

    Partner, Finnegan, Henderson, Farabow, Garrett &Dunner, LLP

    Mark Feldstein, Ph.D., J.D. a Partner at Finnegan, Henderson, Farabow, Garrett &Dunner, LLP, a top tier global law firm specialized in Intellectual Property legal matters.Dr. Feldstein has more than 20 years of experience in U.S. district court and appellate litigation concerning the enforcement of U.S. patent rights and trade secret issues aswell as extensive experience in post-grant trial proceedings (IPRs and PGRs) at the U.S. Patent and Trademark Office. His practice encompasses a range of technologies, including pharmaceuticals, biotechnology, and small molecule chemistry. This includes having litigated patent validity and infringement on behalf of large and small biopharmaceutical companies, such as Eli Lilly, AstraZeneca, Incyte, Cephalon, and Cumberland Pharmaceuticals. In addition, Dr. Feldstein is an adjunct professor of law at Georgetown University Law Center, teaching courses in patent prosecution strategy.He speaks regularly to national and international audiences of both attorneys and scientists on issues of patent strategy, prosecution, and litigation. Dr. Feldstein is also an associate editor for texts published by the American Bar Association Section of Intellectual Property Law on Abbreviated New Drug Application (ANDA) litigation law and strategy, and by AIPLA/Bloomberg BNA on evidence in patent litigations.

    Moderator

    Karsten-Holm.png

    Karsten Holm

    Director of Business Development at Medicilon

    About Medicilon

    Medicilon is a professional pharmaceutical preclinical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.

    We focus on the needs of innovation and development of global pharmaceutical industry, based on the key aspects of R&D of innovative drug, and build acomprehensive technology platform covering drug discovery, pharmacological research and preclinical research key technologies with our rich experiencein serving the Chinese and international biopharmaceutical industry.

    For enquiries, please visit our website www.medicilon.com or email marketing@medicilon.com.

    Scan-to-register.jpg

    Scan to register

    相关新闻